According to a BSE filing dated 18 August 2026, Piramal Pharma Limited (PPL) has successfully completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited. This transaction involved the purchase of 1,46,400 equity shares from existing shareholders for a total cash consideration of approximately ₹76 crores. As a result of this increased investment, PPL’s total shareholding in the company has risen from 33.33% to 74.00%.
The regulatory filing further clarifies that following this acquisition, Yapan Bio has transitioned from being an associate company to becoming a direct subsidiary of Piramal Pharma Limited. The move follows a prior communication on 10 August 2026, regarding the company’s exercise of a call option to acquire the additional equity.
Based in Hyderabad, Yapan Bio is a Contract Development and Manufacturing Organisation (CDMO) that specializes in process development and Phase I/II GMP manufacturing for vaccines and biologics. The company’s financial performance has shown fluctuations recently, with revenue from operations reported at ₹26.34 crores for FY2026, compared to ₹54.40 crores in FY2025 and ₹26.91 crores in FY2024.
Piramal Pharma stated in the filing that the primary strategic goal of this acquisition is to fully integrate Yapan’s advanced large molecule capabilities into its own service offerings.
By doing so, the company aims to enhance its ability to develop and scale complex biologic therapies with improved efficiency. Consequently, the promoter group of Piramal Pharma is now deemed to have an indirect interest in Yapan Bio through this investment.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
